Elanco (ELAN) Animal Health announced the U.S. Department of Agriculture, USDA, has approved TruCan Ultra CIV H3N2/H3N8, a canine influenza vaccine designed to provide broad respiratory disease protection. The approval of TruCan Ultra CIV completes Elanco’s Tru Portfolio of comfortable and convenient combination vaccines made with PureFil Technology, an exclusive process for creating highly purified vaccines designed to reduce adverse reactions and deliver better experiences.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco price target raised to $17 from $16 at Stifel
- Elanco Animal Health Amends Receivables Loan Agreement
- General Mills upgraded, Trade Desk downgraded: Wall Street’s top analyst calls
- Blair upgrades Elanco to Outperform on improved growth outlook
- Elanco upgraded to Outperform from Market Perform at William Blair